Real‑time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin

Liu,Yingzhao; Feng,Yan; Liu,Hongmei; Wu,Jianyong; Tang,Yong; Wang,Qi

doi:10.3892/ol.2018.9223

Real‑time assessment of platinum sensitivity of primary culture from a patient with ovarian cancer with extensive metastasis and the platinum sensitivity enhancing effect by metformin

Authors:
- Yingzhao Liu
- Yan Feng
- Hongmei Liu
- Jianyong Wu
- Yong Tang
- Qi Wang
View Affiliations

Affiliations: Research Department, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China
Published online on: July 27, 2018 https://doi.org/10.3892/ol.2018.9223
Pages: 4253-4262
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to perform a rapid evaluation of the efficiency of commonly used platinum‑based chemotherapy regimens for patients with ovarian cancer with extensive metastases using an in vitro method combined with culturing primary cells and real‑time monitoring, and to further explore the enhanced effect of metformin on susceptibility of ovarian cancer cells to platinum‑based chemotherapy. The primary omental metastatic (OM) cells were isolated from the omentum metastasis of a surgical patient with stage IIIc ovarian carcinoma. Drug sensitivity was evaluated using the xCELLigence system, and screening of the most effective platinum chemotherapy was performed through analysis of cell susceptibility to cisplatin, carboplatin, nedaplatin and paclitaxel or docetaxel alone or in combination. At the same time, this system was used to determine whether metformin was able to increase the sensitivity of cancer cells to platinum chemotherapy. The results revealed that nedaplatin exhibited the most marked cytotoxic effect on the OM cells, followed by those of carboplatin and cisplatin. The addition of docetaxel enhanced the cytotoxic effect, and the combination of platinum and paclitaxel also enhanced the effect. Metformin rapidly increased the sensitivity of cells to platinum‑based chemotherapy, and this effect was dose‑dependent. The sensitivity of OM cells to different platinum‑based regimens was varied. The effect of metformin on chemotherapeutic sensitization of cancer cells is clear in vitro, and the real‑time cell analyzer assay has the potential to assist in determining individualized drug regimens for patients with metastatic ovarian cancer.

View Figures

View References

1	Coleman RL: Ovarian cancer in 2015: Insights into strategies for optimizing ovarian cancer care. Nat Rev Clin Oncol. 13:71–72. 2016. View Article : Google Scholar : PubMed/NCBI
2	Metzger-Filho O, Moulin C and D'Hondt V: First-line systemic treatment of ovarian cancer: A critical review of available evidence and expectations for future directions. Curr Opin Oncol. 22:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kipps E, Tan DS and Kaye SB: Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research. Nat Rev Cancer. 13:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
4	Roshan Moniri M, Young A, Reinheimer K, Rayat J, Dai LJ and Warnock GL: Dynamic assessment of cell viability, proliferation and migration using real time cell analyzer system (RTCA). Cytotechnology. 67:379–386. 2015. View Article : Google Scholar : PubMed/NCBI
5	Pan T, Huang B, Zhang W, Gabos S, Huang DY and Devendran V: Cytotoxicity assessment based on the AUC50 using multi-concentration time-dependent cellular response curves. Anal Chim Acta. 764:44–52. 2013. View Article : Google Scholar : PubMed/NCBI
6	Kho D, MacDonald C, Johnson R, Unsworth CP, O'Carroll SJ, du Mez E, Angel CE and Graham ES: Application of xCELLigence RTCA biosensor technology for revealing the profile and window of drug responsiveness in real time. Biosensors (Basel). 5:199–222. 2015. View Article : Google Scholar : PubMed/NCBI
7	Bailey CJ: Metformin: Historical overview. Diabetologia. 60:1566–1576. 2017. View Article : Google Scholar : PubMed/NCBI
8	Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
9	Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kumar S, Meuter A, Thapa P, Langstraat C, Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake is associated with better survival in ovarian cancer: A case-control study. Cancer. 119:555–562. 2013. View Article : Google Scholar : PubMed/NCBI
11	Bar D, Lavie O, Stein N, Feferkorn I and Shai A: The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 207:227–231. 2016. View Article : Google Scholar : PubMed/NCBI
12	Patel S, Singh N and Kumar L: Evaluation of effects of metformin in primary ovarian cancer cells. Asian Pac J Cancer Prev. 16:6973–6979. 2015. View Article : Google Scholar : PubMed/NCBI
13	Mutch DG and Prat J: 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 133:401–404. 2014. View Article : Google Scholar : PubMed/NCBI
14	Metzgerfilho O, Moulin C and D'hondt V: First-line systemic treatment of ovarian cancer: A critical review of available evidence and expectations for future directions. Curr Opin Oncol. 22:513–520. 2010. View Article : Google Scholar : PubMed/NCBI
15	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
16	Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, et al: SEER cancer statistics review, 1975–2014. National Cancer Institute; Bethesda MD: https://seer.cancer.gov/csr/1975_2014/based on November 2016 SEER data submission, posted to the SEER web site. April. 2017
17	Mei L, Chen H, Wei DM, Fang F, Liu GJ, Xie HY, Wang X, Zou J, Han X and Feng D: Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev. 29:CD0074142013.
18	Davidson B and Tropé CG: Ovarian cancer: Diagnostic, biological and prognostic aspects. Womens Health (Lond). 10:519–533. 2014. View Article : Google Scholar : PubMed/NCBI
19	Holmes D: Ovarian cancer: Beyond resistance. Nature. 527:S2172015. View Article : Google Scholar : PubMed/NCBI
20	Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
21	Kischkel FC, Meyer C, Eich J, Nassir M, Mentze M, Braicu I, Kopp-Schneider A and Sehouli J: Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test). J Ovarian Res. 10:722017. View Article : Google Scholar : PubMed/NCBI
22	O Donnell RL, Mccormick A, Mukhopadhyay A, Woodhouse LC, Moat M, Grundy A, Dixon M, Kaufman A, Soohoo S, Elattar A, et al: The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS One. 9:e906042014. View Article : Google Scholar : PubMed/NCBI
23	Kar R, Chawla D, Gupta B, Mehndiratta M, Wadhwa N and Agarwal R: Establishment of primary cell culture from ascitic fluid and solid tumor obtained from epithelial ovarian carcinoma patients. Int J Gynecol Cancer. 27:2000–2005. 2017. View Article : Google Scholar : PubMed/NCBI
24	Robinson DR, Wu YM, Lonigro RJ, Vats P, Cobain E, Everett J, Cao X, Rabban E, Kumar-Sinha C, Raymond V, et al: Integrative clinical genomics of metastatic cancer. Nature. 548:297–303. 2017. View Article : Google Scholar : PubMed/NCBI
25	Gillet JP and Gottesman MM: Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sherman-Baust CA, Becker KG, Wood Iii WH, Zhang Y and Morin PJ: Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res. 4:212011. View Article : Google Scholar : PubMed/NCBI
27	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
28	Shen D, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
29	Sato S and Itamochi H: Ovarian cancer and drug resistance. Curr Obstet Gynecol Rep. 4:18–25. 2015. View Article : Google Scholar
30	Rattan R, Giri S, Hartmann LC and Shridhar V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 15:166–178. 2011. View Article : Google Scholar : PubMed/NCBI
31	Do MT, Kim HG, Choi JH and Jeong HG: Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic Biol Med. 74:21–34. 2014. View Article : Google Scholar : PubMed/NCBI
32	Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK and Buckanovich RJ: Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol. 127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
33	Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012. View Article : Google Scholar : PubMed/NCBI
34	Gwak H, Kim Y, An H, Dhanasekaran DN and Song YS: Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer. Mol Carcinog. 56:349–358. 2017. View Article : Google Scholar : PubMed/NCBI
35	Wang H, Zhang Z, Wei X and Dai R: Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells. J Ovarian Res. 8:32015. View Article : Google Scholar : PubMed/NCBI
36	Li P, Zhao M, Parris AB, Feng X and Yang X: p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. Biochem Biophys Res Commun. 464:1267–1274. 2015. View Article : Google Scholar : PubMed/NCBI
37	Gao ZY, Liu Z, Bi MH, Zhang JJ, Han ZQ, Han X, Wang HY, Sun GP and Liu H: Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med. 11:1700–1706. 2016. View Article : Google Scholar : PubMed/NCBI
38	Zhang R, Zhang P, Wang H, Hou D, Li W, Xiao G and Li C: Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther. 6:2622015. View Article : Google Scholar : PubMed/NCBI
39	Gonzalez DM and Medici D: Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 7:re82014. View Article : Google Scholar : PubMed/NCBI
40	Ling S, Song L, Fan N, Feng T, Liu L, Yang X, Wang M, Li Y, Tian Y, Zhao F, et al: Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. Int J Oncol. 50:297–309. 2017. View Article : Google Scholar : PubMed/NCBI
41	Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer research. 74:1–4795. 2014. View Article : Google Scholar